A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors

NCT00422682 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumors

Interventions

DRUG: bsi-201 + topotecan
DRUG: bsi-201 + temozolomide
DRUG: bsi-201 + gemcitabine
DRUG: bsi-201 + carboplatin/paclitaxel

Sponsor

Sanofi